MedKoo Cat#: 574642 | Name: CP-316819
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CP-316819 is a glycogen phosphorylase inhibitor.

Chemical Structure

CP-316819
CP-316819
CAS# 186392-43-8

Theoretical Analysis

MedKoo Cat#: 574642

Name: CP-316819

CAS#: 186392-43-8

Chemical Formula: C21H22ClN3O4

Exact Mass: 415.1299

Molecular Weight: 415.87

Elemental Analysis: C, 60.65; H, 5.33; Cl, 8.52; N, 10.10; O, 15.39

Price and Availability

Size Price Availability Quantity
10mg USD 385.00 2 Weeks
50mg USD 1,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
CP 316819; CP-316819; CP316819
IUPAC/Chemical Name
5-Chloro-N-[(1S,2R)-2-hydroxy-3-(methoxymethylamino)-3-oxo-1-(phenylmethyl)propyl]-1H-indole-2-carboxamide
InChi Key
FAKGUYOEMJMLCN-PKOBYXMFSA-N
InChi Code
InChI=1S/C21H22ClN3O4/c1-29-12-23-21(28)19(26)17(9-13-5-3-2-4-6-13)25-20(27)18-11-14-10-15(22)7-8-16(14)24-18/h2-8,10-11,17,19,24,26H,9,12H2,1H3,(H,23,28)(H,25,27)/t17-,19+/m0/s1
SMILES Code
O=C(C(N1)=CC2=C1C=CC(Cl)=C2)N[C@@H](CC3=CC=CC=C3)[C@@H](O)C(NCOC)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 415.87 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1. Baker et al (2005) Glycogen phosphorylase inhibition in type 2 diabetes therapy: a systematic evaluation of metabolic and functional effects in rat skeletal muscle. Diabetes 54 2453 PMID: 16046314 2. Freeman et al (2006) Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation site of the enzyme. Br.J.Pharmacol. 149 775 PMID: 17016495 3. Suh et al (2007) Astrocyte glycogen sustains neuronal activity during hypoglycemia: studies with the glycogen phosphorylase inhibitor CP-316,819 ([R-R*,S*]-5-chloro-N-[2-hydroxy-3-(methoxymethylamino)-3-oxo-1-(phenylmethyl)propyl]-1H-indole-2-ca J.Pharmacol.Exp.Ther. 321 45 PMID: 17251391